In vitroandin vivoevaluation of the inhibition potential of risperidone toward clozapine biotransformation
Authors:
- 15 October 2009
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (4) , 574-579
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The clozapine (CLZ)–risperidone (RISP) combination is effective in schizophrenic patients but may lead to elevated plasma CLZ concentrations and adverse effects.• Reports of potential inhibitory effects of RISP on cytochrome P450 (CYP)‐dependent CLZ oxidation have been inconsistent.• It has been suggested that variations in expression of CLZ/RISP oxidases, such as CYPs 1A2, 2D6 and 3A4, may influence inhibitory interactions.WHAT THIS STUDY ADDS• Inhibition of CLZ biotransformation by RISP was assessed in microsomal fractions that expressed varying amounts of CYPs 1A2, 2D6 and 3A4.• RISP did not inhibit the formation of major oxidized CLZ metabolites, regardless of the CYP expression profile; findings from anin vivostudy in patients were consistent with this finding.• Pharmacokinetic interactions due to the RISP–CLZ combination are unlikely to involve CYPs.AIMS: To study the impact of risperidone (RISP) on clozapine (CLZ) biotransformationin vitroin microsomal fractions containing varying expression of CYP oxidases andin vivoin patients.METHODS: Human liver microsomes (n= 11) were assessed for expression of CYPs 1A2, 2D6 and 3A4, because these enzymes mediate RISP and CLZ oxidation. Inhibition of CLZ oxidation by RISP was assessed. Plasma CLZ elimination was estimated in patients with schizophrenia who received either CLZ alone or the CLZ–RISP combination (n= 10 per group).RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions. (ii) RISP did not inhibit CLZ oxidation, regardless of variations in CYP expression. (iii) RISP co‐administration did not impair CLZ clearance.CONCLUSIONS: No evidence was found for CYP‐mediated inhibitory or pharmacokinetic interactions between RISP and CLZ. Occasional literature reports of such interactions may involve other pathways that participate in CLZ disposition.Keywords
This publication has 25 references indexed in Scilit:
- Interindividual Variation in Relative CYP1A2/3A4 Phenotype Influences Susceptibility of Clozapine Oxidation to Cytochrome P450-Specific Inhibition in Human Hepatic MicrosomesDrug Metabolism and Disposition, 2008
- Serum concentrations of risperidone and 9‐OH risperidone following intramuscular injection of long‐acting risperidone compared with oral risperidone medicationActa Psychiatrica Scandinavica, 2006
- Clozapine Alone versus Clozapine and Risperidone with Refractory SchizophreniaNew England Journal of Medicine, 2006
- Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled TrialAmerican Journal of Psychiatry, 2005
- A Pilot Study on Risperidone MetabolismThe Journal of Clinical Psychiatry, 1999
- Risperidone and clozapine combination for the treatment of refractory schizophreniaActa Psychiatrica Scandinavica, 1999
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapineBritish Journal of Clinical Pharmacology, 1997
- Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.British Journal of Clinical Pharmacology, 1994
- The Assay of Clozapine and N-Desmethylclozapine in Human Plasma by High-Performance Liquid ChromatographyTherapeutic Drug Monitoring, 1991
- Drug metabolism in cirrhosisBiochemical Pharmacology, 1986